While the IL‐4/IL‐13 inhibitor dupilumab is the standard systemic therapy for moderate‐to‐severe AD, its effectiveness within the context of PAD is unclear, with evidence limited to isolated case reports [3]. This evidence concerns the gene IL4 and peripheral arterial disease.